Using probiotics to help people with Long COVID
Investigation of the Use of a Probiotic Supplement in People With Long COVID
This study is testing whether taking a probiotic supplement can help people with Long COVID feel better by reducing their symptoms.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sheffield Hallam University Academic / other |
| Locations | 1 site (Sheffield) |
| Trial ID | NCT05975034 on ClinicalTrials.gov |
What this trial studies
This investigation involves a double-blinded randomized trial to evaluate the effectiveness of a probiotic supplement in reducing symptoms associated with Long COVID. A total of 240 participants will be randomly assigned to receive either the probiotic or a placebo for a duration of twelve weeks. Participants will monitor their symptoms through an app and complete online questionnaires at specified intervals. Additionally, a subgroup of 60 participants will undergo laboratory tests to assess blood markers, cognitive function, and gut microbiome changes.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals who have been diagnosed with Long COVID, experiencing persistent symptoms for at least 12 weeks following a confirmed or suspected COVID-19 infection.
Not a fit: Patients with significant co-morbidities or pre-existing conditions such as hypertension, diabetes, or cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new therapeutic option for alleviating symptoms in individuals suffering from Long COVID.
How similar studies have performed: While the use of probiotics in various conditions has been explored, this specific approach for Long COVID is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Long COVID defined as National Institute for Health and Care Excellence (NICE) criteria for Long COVID (Persistent symptoms at least 12 weeks after a confirmed or suspected Covid-19 infection). - Exclusion Criteria: Significant co-morbidities - no pre-existing diagnosis of hypertension, diabetes, cerebrovascular, cardiovascular or peripheral vascular disease, coagulopathy or haematological disorder or current or recent cancer. -
Where this trial is running
Sheffield
- Sheffield Hallam University — Sheffield, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Caroline Dalton, PhD — Sheffield Hallam University
- Study coordinator: Caroline Dalton, PhD
- Email: c.f.dalton@shu.ac.uk
- Phone: 44-114-225-3695
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.